Can Drugs Targeting Tumor Microenvironment Unleash Cancer Vaccine Potential?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cancer vaccines in the past have failed clinically but may have succeeded biologically, according to Roche R&D exec Hy Levitsky. The immunosuppressive tumor microenvironment must be circumvented if the vaccine response is to be effective – and Roche thinks its immuno-oncology pipeline could do the trick.
You may also be interested in...
Cancer Vaccines 2.0
A trio of well-funded and star-studded new private biotechs have emerged in recent months to develop personalized cancer vaccines against tumor-specific neoantigens. After years of failure in the space, will Neon Therapeutics, Gritstone Oncology, Caperna and the rest of the field catch the wave of immuno-oncology science and sentiment?
On The Threshold Of The Tumor Microenvironment
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.